Ep 86: Tudriqev (RP1) FDA Approval
Melanoma Matters

Ep 86: Tudriqev (RP1) FDA Approval

2026年8月25日52分钟

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data. It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.

播放本集

这一集暂时还没有文字稿

你仍然可以在播放器中收听。有文字稿的节目,点任意单词就能看到释义。